Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients.
Adenocarcinoma
/ immunology
Adult
Aged
Aged, 80 and over
Colectomy
Colorectal Neoplasms
/ immunology
Female
Humans
Lymphocyte Count
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Observer Variation
Predictive Value of Tests
Reproducibility of Results
Staining and Labeling
Time Factors
Treatment Outcome
Young Adult
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
20
11
2019
medline:
29
7
2020
entrez:
20
11
2019
Statut:
ppublish
Résumé
The presence of increased tumor-infiltrating lymphocytes (TILs) is established as a positive prognostic factor in many malignancies including colorectal carcinoma (CRC). However, multiple different approaches have been used to assess TILs. In 2014, the International TILs Working Group (ITWG) proposed a standardized methodology for evaluating TILs, initially in the context of breast cancer, but subsequently expanded to other malignancies. To date, the efficacy of the ITWG system has not been investigated in a large cohort of all-stage CRC. We, therefore, sought to validate this system in CRC. We used the ITWG system to assess the density of stromal TILs in an unselected cohort of 1034 CRC patients undergoing primary tumor resection at our institution. The percentage TILs' score was categorized into 3 groups: low (0% to 10%), intermediate (15% to 50%), and high (55% to 100%). The mean survival was 53, 67, and 75 months, respectively (P=0.0001). This survival benefit remained statistically significant in multivariate analyses (P=0.0001) and subgroup analyses of mismatch repair-proficient CRCs (P=0.0001), mismatch repair-deficient CRCs (P=0.031), BRAFV600E-mutant CRCs (P=0.0001), and BRAF wild-type CRCs (P=0.001). The predictive value of TILs assessed using the ITWG system was superior to the assessment of intraepithelial lymphocyte performed prospectively using a standard system requiring ≥5 lymphocytes per high-powered field in direct contact with tumor cells or between tumor clusters. We conclude that the ITWG system for assessing TILs is a powerful predictor of all-cause survival in CRC independent of many prognostic factors and superior to the assessment of intraepithelial lymphocytes using a traditional system.
Identifiants
pubmed: 31743129
doi: 10.1097/PAS.0000000000001409
pii: 00000478-202004000-00012
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-544Références
Giraldo NA, Peske JD, Sautes-Fridman C, et al. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch. 2019;474:463–474.
Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumours. Adv Anat Pathol. 2017;24:311–335.
Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24:235–251.
Linette GP, Carreno BM. Tumor-infiltrating lymphocytes in the checkpoint inhibitor era. Curr Hematol Malig Rep. 2019;14:286–291.
Kong JC, Guerra GR, Pham T, et al. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2019;62:498–508.
Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41:2645–2654.
Royal College of Pathologists of Australasia (RCPA). Colorectal cancer structured reporting protocol (3rd edition); 2016. Available at: www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols/Gastrointestinal/Protocol-colorectal-cancer. Accessed July 5, 2019.
College of American Pathologist (CAP). Cancer Protocol Templates. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum; 2017. Available at: www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates. Accessed August 30, 2019.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014;26:259–271.
Toon CW, Walsh MJ, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013;37:1592–1602.
Reagh J, Clarkson A, Bullock M, et al. Real world experience of BRAFV600E mutation specific immunohistochemistry in colorectal carcinoma. Pathology. 2018;50:342–344.
Heikkinen I, Bello I, Wahab A, et al. Assessment of tumor-infiltrating lymphocytes predicts the behavior of early-stage oral tongue cancer. Am J Surg Pathol. 2019;43:1392–1396.
Iseki Y, Shibutani M, Maeda K, et al. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H&E)-stained tumor sections. PLoS One. 2018;13:e0192744.
Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;38:511–520.
Meropol NJ. Ongoing challenge of stage II colon cancer. J Clin Oncol. 2011;29:3346–3348.
Vachani C, Giantonio B. Stage II colon cancer: to treat or not to treat? 2013. Available at: www.oncolink.org/types/article.cfm?c=124&id=9621. Accessed July 8, 2019.
Gray R, Barnwell J, McConkey C, et al. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029.
O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–3382.
Kannarkatt J, Joseph J, Kurniali PC, et al. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13:233–241.
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16:359–369.
Gao S, Tibiche C, Zou J, et al. Identification and Construction of Combinatory Cancer Hallmark–based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer. JAMA Oncol. 2016;2:37–45.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
Galon J, Mlecnik B, Marliot F, et al. Validation of the immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol. 2016;34 (suppl):3500.
Matsutani S, Shibutani M, Maeda K, et al. Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer. Oncotarget. 2018;9:15180–15197.
Eriksen AC, Sorensen FB, Lindebjerg J, et al. The prognostic value of tumor-infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study. Transl Oncol. 2018;11:979–987.
Ko Y, Pyo J. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers. 2019;34:132–138.
Park JH, McMillan DC, Edwards J, et al. Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. Oncoimmunology. 2016;5:e1098801.
Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg. 2004;91:469–475.
Rozek LS, Schmit SL, Greenson JK, et al. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst. 2016;108:djw027.
Alexander J, Watanabe T, Wu T, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–535.
Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol. 2003;27:563–570.
Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–2422.
Jenkins MA, Hayashi S, O’Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007;133:48–56.
Asad Umar C, Boland R, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.
Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33:1639–1645.